Prime Medicine Statistics

Total Valuation

Prime Medicine has a market cap or net worth of $499.50 million. The enterprise value is $517.48 million.

Market Cap	499.50M
Enterprise Value	517.48M

Important Dates

The last earnings date was Thursday, August 7, 2025, before market open.

Earnings Date	Aug 7, 2025
Ex-Dividend Date	n/a

Share Statistics

Prime Medicine has 131.10 million shares outstanding. The number of shares has increased by 24.42% in one year.

Current Share Class	131.10M
Shares Outstanding	131.10M
Shares Change (YoY)	+24.42%
Shares Change (QoQ)	-1.30%
Owned by Insiders (%)	20.32%
Owned by Institutions (%)	36.33%
Float	58.40M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	97.46
Forward PS	n/a
PB Ratio	8.20
P/TBV Ratio	8.21
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	104.31
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 3.56, with a Debt / Equity ratio of 1.97.

Current Ratio	3.56
Quick Ratio	2.99
Debt / Equity	1.97
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -154.81% and return on invested capital (ROIC) is -60.96%.

Return on Equity (ROE)	-154.81%
Return on Assets (ROA)	-47.39%
Return on Invested Capital (ROIC)	-60.96%
Return on Capital Employed (ROCE)	-83.39%
Revenue Per Employee	$23,182
Profits Per Employee	-$931,192
Employee Count	214
Asset Turnover	0.02
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -7.64% in the last 52 weeks. The beta is 2.41, so Prime Medicine's price volatility has been higher than the market average.

Beta (5Y)	2.41
52-Week Price Change	-7.64%
50-Day Moving Average	3.19
200-Day Moving Average	2.67
Relative Strength Index (RSI)	50.75
Average Volume (20 Days)	4,643,485

Short Selling Information

The latest short interest is 21.85 million, so 16.67% of the outstanding shares have been sold short.

Short Interest	21.85M
Short Previous Month	21.66M
Short % of Shares Out	16.67%
Short % of Float	37.41%
Short Ratio (days to cover)	3.94

Income Statement

In the last 12 months, Prime Medicine had revenue of $4.96 million and -$199.28 million in losses. Loss per share was -$1.57.

Revenue	4.96M
Gross Profit	-149.46M
Operating Income	-204.22M
Pretax Income	-217.55M
Net Income	-199.28M
EBITDA	-197.38M
EBIT	-204.22M
Loss Per Share	-$1.57

Full Income Statement

Balance Sheet

The company has $101.75 million in cash and $119.74 million in debt, giving a net cash position of -$17.99 million or -$0.14 per share.

Cash & Cash Equivalents	101.75M
Total Debt	119.74M
Net Cash	-17.99M
Net Cash Per Share	-$0.14
Equity (Book Value)	60.86M
Book Value Per Share	0.46
Working Capital	87.18M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$99.94 million and capital expenditures -$7.06 million, giving a free cash flow of -$107.00 million.

Operating Cash Flow	-99.94M
Capital Expenditures	-7.06M
Free Cash Flow	-107.00M
FCF Per Share	-$0.82

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	-4,116.57%
Pretax Margin	-4,016.83%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Prime Medicine does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-24.42%
Shareholder Yield	-24.42%
Earnings Yield	-39.90%
FCF Yield	-21.42%

Analyst Forecast

The average price target for Prime Medicine is $8.88, which is 133.07% higher than the current price. The consensus rating is "Buy".

Price Target	$8.88
Price Target Difference	133.07%
Analyst Consensus	Buy
Analyst Count	6
Revenue Growth Forecast (5Y)	58.79%
EPS Growth Forecast (5Y)	-13.30%

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Prime Medicine has an Altman Z-Score of -4.95 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-4.95
Piotroski F-Score	3